Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
METANOVA trial: what clinicians have said so far
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- NCT06150417 ↗
- Recruiting
- Case Comprehensive Cancer Center
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on METANOVA (de novo oligometastatic prostate cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on METANOVA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 10 posts on X | |
| 2 YouTube videos | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Prostate Cancer; Malignant Neoplasm of Prostate; Secondary Malignant Neoplasm of Prostate
- Interventions
- Androgen deprivation therapy (ADT); Androgen receptor signaling inhibitor (ARSI); Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT); Metastasis directed radiotherapy (MDRT)
- Arms
- Standard of Care (SOC) · Active comparator
- SOC + MDRT · Experimental
- Enrollment
- 200 (estimated)
- Primary outcomes
- Failure-free survival (FFS)
- Sponsor
- Case Comprehensive Cancer Center with National Institutes of Health (NIH), National Cancer Institute (NCI)
- Start
- Jul 1, 2024
- Primary completion
- Dec 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06150417 · updated Sep 15, 2026
Publications
linked from the registry- Lichtman-Mikol S, Lang JM, Nagar H, Zuhour R, Chaung KV, Zaorsky NG, Roy S, Mendiratta PM, Shoag JE, Janopaul-Naylor JR, Khani F, Schaeffer EM, Kyriakopoulos CE, Barata P, Brown JR, Garcia JA, Barbieri CE, Sun Y, Choyke PL, Spratt DE, Jia AY. Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA. BMJ Open. 2026 Oct 6;16(10):e116331. doi: 10.1136/bmjopen-2026-116331. PubMed 42838582